Share on StockTwits

AstraZeneca plc (NYSE:AZN) was upgraded by stock analysts at Danske to a “hold” rating in a report issued on Tuesday.

AstraZeneca plc (NYSE:AZN) opened at 70.64 on Tuesday. AstraZeneca plc has a 52-week low of $46.87 and a 52-week high of $82.68. The stock’s 50-day moving average is $71.18 and its 200-day moving average is $63.64. The company has a market cap of $89.077 billion and a P/E ratio of 49.22. AstraZeneca plc also was the recipient of unusually large options trading activity on Monday. Stock investors purchased 73,299 call options on the stock. This represents an increase of approximately 426% compared to the typical daily volume of 13,940 call options.

AstraZeneca plc (NYSE:AZN) last released its earnings data on Thursday, April 24th. The company reported $1.17 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.23 by $0.06. The company had revenue of $6.42 billion for the quarter, compared to the consensus estimate of $6.32 billion. During the same quarter in the prior year, the company posted $1.41 earnings per share. The company’s quarterly revenue was up .5% on a year-over-year basis. Analysts expect that AstraZeneca plc will post $4.23 EPS for the current fiscal year.

Other equities research analysts have also recently issued reports about the stock. Analysts at Prime Wealth reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Monday. Separately, analysts at Panmure Gordon downgraded shares of AstraZeneca plc from a “buy” rating to a “hold” rating in a research note on Monday. Finally, analysts at Leerink Swann downgraded shares of AstraZeneca plc from an “outperform” rating to a “market perform” rating in a research note on Monday. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $64.50.

AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.